# European Network of Gynaecological Oncological Trial groups (ENGOT)

Prof. Nicoletta Colombo, ENGOT Past Chair

# ENGOT HISTORY

# European Network for Gynaecological Oncological Trial Groups

ENGOT
European Network of Gynaecological Oncological Trial groups

## Founded in Berlin 2007!


Andreas du Bois

Ignace Vergote

# ENGOT mission and vision

- ENGOT is a platform that guarantees that the European spirit and culture is incorporated into the medical progress in gynaecological oncology, and that all European patients and countries can participate in an active way in clinical research and progress.

- The ultimate goal is to bring the best treatment to gynaecological cancer patients through the best science and enabling every patient in every European country to access a clinical trial.

ENGOT
European Network of Gynaecological Oncological Trial groups

# Who we are?

ENGOT
European Network of
Gynaecological Oncological Trial groups

- ENGOT is a **network of national and regional cooperative groups**, ENGOT coordinates and promotes clinical trials within Europe on patients with gynaecological cancer.

- This coordination is particularly relevant for academic clinical trials, translational research, research on rare diseases, and for clinical trials sponsored by the industry to perform multinational studies in Europe.

- ENGOT consists of **21 groups from 33 countries**.

# ENGOT MEMBERS

engot.esgo.org

ENGOT
European Network of Gynaecological Oncological Trial groups

## 21 ENGOT GROUPS

## 33 COUNTRIES

# Democratic structure of ENGOT

- **ENGOT Chairs** are changed every 2 years, coming each time from a different ENGOT group. Current ENGOT Chairs (2024-2026):

**Prof. Isabelle Ray-Coquard**
Clinical Chair
(GINECO, France)

**Elena Biagioli**
Operational Chair
(MaNGO, Italy)

- **ENGOT Assembly** open for all ENGOT members participation is held twice a year in the spring and autumn.

- **ENGOT Strategic group** is formed by groups leading the ENGOT trials.

# WHERE DO THE ENGOT TRIALS COME FROM?
## part1

**Clinical need**

**Idea**

**Discussion and refinement**

In your home study group

**Find potential sponsors…**

…industry

…or public finding

**ENGOT GA or strategic group**

Bring **exposè** with **LoI** of sponsorship for further discussion and refinement

**Writing and prepare**

**Protocol** writing and prepare study **infrastructure**

**Back to ENGOT**

- Final **vote** (number)
- **Lead** group
- Seeking **cooperation**

ENGOT
European Network of Gynaecological Oncological Trial groups

# WHERE DO THE ENGOT TRIALS COME FROM?
## part2

Identify a **clinical need**

Buy a **drug**

**Economical** need

Make numerous **advisory boards** to develop an **idea**

Plan a pure **industry** trial

Select **PI**

Pure pharma trial

Contact **academic** study groups

Study group brings protocol draft to **ENGOT GA / strategic groups** for further **discussion** and **refinement**

ENGOT voting on study and selects / confirms **lead group**

Lead groups seeks **cooperation**

ENGOT
European Network of Gynaecological Oncological Trial groups

# How do we run a trial in ENGOT?

ENGOT
European Network of
Gynaecological Oncological Trial groups

## European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015

*Andreas du Bois, MD, PhD, Alexander Reuss, Eric Pujade-Lauraine, MD, Sandro Pignata, MD, Jonathan Ledermann, MD, Antonio Casado, MD, Jalid Sehouli, MD, Mansoor Mirza, MD, Nicoletta Colombo, MD, Christian Marth, MD, Els Witteveen, MD, Jose Del Campo, MD, Paula Calvert, MD, Gerassimos Aravantinos, MD, Mehmet Ali Vardar, MD, Ate G.J. van der Zee, MD, Jacob Korach, MD, Cagatay Taskiran, MD, Mathias Fehr, MD, Ros Glasspool, MD, Jacobus Pfisterer, MD, David Cibula, MD, PhD, Ignace Vergote, MD, PhD, and On behalf of the member trial groups of the European Network of Gynaecological Oncological Trial Groups (ENGOT)*

**Abstract:** The first version of ENGOT's Requirements for Trials Between Academic Groups and Industry Partners in Europe was published 2010. This first update integrates the experiences made by the ENGOT network and the cooperative group studies while performing, analyzing, and publishing -among others - three large phase III trials. Furthermore, progress in European legislation and its impact on clinical studies in Europe have been considered in this update process.

**Key Words:** Academic groups, ENGOT, Requirements, Trials

Received April 14, 2015, and in revised form Month DD, YYYY.
Accepted for publication April 15, 2015.

(*Int J Gynecol Cancer* 2015;00: 00–00)

## Roadmap for the European Network of Gynaecological Trial Groups (ENGOT) Trials

*Ignace Vergote, MD, PhD, Gabriele Elser, RN, Benedicte Votan, MSc, Laura Farrelly, BSc(hons), RN, Joke De Roover, PhD, Jane Bryce, RN, MSN, Andreas du Bois, MD, PhD, and On behalf of the member trial groups of the European Network of Gynaecological Trial groups (ENGOT)*

**Abstract:** The European Network for Gynaecological Oncological Trial groups (ENGOT) is a research network of the European Society of Gynaecological Oncology and was founded in Berlin in October 2007. Earlier, we reported on the ENGOT minimal requirements for trials between academic groups and pharmaceutical companies. In this paper, we summarize the roadmap for performing trials in the ENGOT framework. In this roadmap, we define how an ENGOT trial should be set up and discuss the following items: What are the conditions to classify a study as an ENGOT trial? What is an ENGOT protocol? How are an ENGOT protocol, informed consent (ICF), and case report form (CRF) produced? How is the center selection and feasibility performed in ENGOT trials? How are regulatory and operational tasks handled? How should a confidentiality agreement between the industry and the whole ENGOT network be negotiated? How are contracts made between the industry and ENGOT and between ENGOT groups? How are funding, insurance, and communication flow arranged in ENGOT trials? What are the requirements for conducting substudies and what are the tasks for the leading group in an ENGOT trial? A template of a confidentiality agreement, a checklist of ENGOT criteria for new study proposals, and guidelines for authorship are also provided.

**Key Words:** ENGOT, Clinical trials, Gynecologic oncology, Trial, Management, Academic

(*Int J Gynecol Cancer* 2013;23: 1339–1343)

# Pre-requisites of a ENGOT trial

ENGOT
European Network of Gynaecological Oncological Trial groups

1. One protocol developed and agreed upon by the lead study group and the industry partner, reviewed, and approved by the trial steering committee.
2. Both the industry partner and the lead study group will agree on 1 common statistical analysis plan (SAP) or produce their own SAPs.
   - In case of 2 different SAPs, the leading study group's SAP will be the basis for all academic publications.
3. One database agreed on by the lead study group and the industry partner.
4. One case report form
5. 50+% ENGOT centers
6. Center selection by ENGOT groups in ENGOT countries
7. Lead group is responsible for publication

# COOPERATION WITH PHARMA COMPANIES

# ENGOT partnership with industry
# Design of clinical trials

- Patient oriented
- Focus on unmet medical needs
- Academic participation and “validation” of clinical trials design is a plus for credibility
- Clinically-oriented translational research designs (Translational Research Group)
- Opportunity of helping in the development of the pipeline from the beginning (from Phase I/II Group to phase III design)

ENGOT
European Network of Gynaecological Oncological Trial groups

# ENGOT partnership with industry

Apart of clinical trials ENGOT can:

- Organize Advisory Board meetings
- Organize Steering committee meetings
- Organize other kinds of meetings
- Help with organization of industry symposia at congresses

- In case you are interested please contact the ENGOT office at engot@esgo.org

ENGOT
European Network of Gynaecological Oncological Trial groups

# ENGOT PARTNERSHIP

engot.esgo.org

# The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership

*Christian Marth, ENGOT Chair, AGO-Austria, Andreas du Bois, ENGOT Vice-Chair, AGO Germany, Christian Schauer (AGO-Austria), Andreas du Bois (AGO-Germany), Antonio Casado (EORTC GCG), Ignace Vergote (BGOG), José Maria del Campo (GEICO), Athina Goudopoulou (HECOG), Eric Pujade-Lauraine (GINECO), Ilan Bruchim (ISGO), Nicoletta Colombo (ManGO), Sandro Pignata (MITO), Jonathan Ledermann (NCRI/MCR), Radoslav Chekerov (NOGGO), Mansoor Raza Mirza (NSGO), Anneke Westermann (DGOG), Ros Glasspool (SGTCG), Cagatay Taskiran (TSGO), Mathias Fehr (SAKK), and David Cibula (CEEGOG)*

ENGOT
European Network of Gynaecological Oncological Trial groups

GYNAECOLOGICAL CANCER ACADEMY

ENGOT
European Network of Gynaecological Oncological Trial groups

# Cooperation with GOG and APGOT and more

Prof. Nicoletta Colombo

Date: 14 November 2024

# GOG Foundation

- The Gynecologic Oncology Group, the earliest version of today's GOG Foundation, was **founded in 1970** and housed within the American College of Obstetricians Gynecologists.

- It later became an independent nonprofit organisation, providing a corporate home for NCI-sponsored cooperative group clinical trials.

- Since then, the GOG developed into a large organization with a robust trial portfolio that enjoyed extensive support from the gynecologic cancer research community.

- Dr **Thomas Herzog** is the current president

GOG FOUNDATION®
*Transforming the standard of care™*

GOG PARTNERS

- Consulting/Strategy
- Clinical Trial Design
- Site Management
- Education

NRG ONCOLOGY
*Advancing Research. Improving Lives.™*

- CTEP and other core focused items

GOG FOUNDATION®
Transforming the standard of care

## OUR MISSION

To conduct clinical and translational research that positively impacts patients through the prevention and treatment of gynecologic malignancies

## OUR VISION

To be the premier collaborative network for transformative research in gynecologic malignancies

GOG PARTNERS
A GOG Foundation Program

# ENGOT/GOG-F cooperation milestones

MAIN DOCUMENTS:

- **Joint ENGOT and GOG-F Requirements for Trials with Industry partners** published on 18 July 2019
- **Non-disclosure agreement between ENGOT and GOG-F** signed on 19 November 2019
- **ENGOT-GOG-F Publication Guidelines** developed in April 2021

REGULAR MEETINGS:

- **ENGOT-GOG-F Liaison Committee** meeetings are held every 3 months

# ENGOT/GOG-F liaison committee

Original Article

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

## Joint ENGOT and GOG Foundation requirements for trials with industry partners

Ignace Vergote,[1] Robert L Coleman,[2] Sandro Pignata,[3] Michael A Bookman,[4] Christian Marth,[5] Thomas J Herzog,[6] Antonio Gonzalez Martin,[7] Larry J Copeland,[8] On behalf of The European Network of Gynaecological Oncological Trial Groups (ENGOT) and The GOG Foundation, Inc



For numbered affiliations see end of article.

**Correspondence to**
Professor Ignace Vergote, Gynaecological Oncology,

### HIGHLIGHTS

- The European Network of Gynaecological Oncological Trial Groups (ENGOT) and The GOG Foundation present for the first time the joint requirements for trials with industry.
- Guidelines are presented for sponsorship, trial steering committee, and development of a protocol, database, and statistical plan.
- A roadmap is presented for site selection, contracts, press releases, publications, and a communication plan.

Gynecologic Oncology 154 (2019) 255–258

Contents lists available at ScienceDirect

Gynecologic Oncology

journal homepage: www.elsevier.com/locate/ygyno

Clinical commentary

## Joint ENGOT and GOG Foundation requirements for trials with industry partners☆

Ignace Vergote [a,*,1], Robert L. Coleman [b,1], Sandro Pignata [c], Michael A. Bookman [d], Christian Marth [e], Thomas J. Herzog [f], Antonio Gonzalez-Martin [g,2], Larry J. Copeland [h,2], on behalf of the European Network of Gynaecological Oncological Trial Groups (ENGOT) and The GOG Foundation Inc.

[a] ENGOT/BGOG and University Hospital Leuven, Gynaecological Oncology, Leuven Cancer Institute, Herestraat 49, 3000 Leuven, Belgium, European Union
[b] GOG-F and Gynecologic Oncology & Reproductive Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA
[c] ENGOT/MITO Istituto Nazionale Tumori IRCCS Fondazione Pascale Napoli, Italy
[d] GOG-F and Gynecologic Oncology Therapeutics, Kaiser Permanente San Francisco, San Francisco, USA
[e] ENGOT/A-AGO and Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
[f] GOG-F and Gynecologic Oncology, University of Cincinnati, Cincinnati, Ohio, USA
[g] ENGOT/GEICO and Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain
[h] GOG-F and Gynecologic Oncology, Ohio State University Wexner Medical Center and JamesCare Gynecologic Oncology at Mill Run, Columbus, Ohio, USA

ENGOT
European Network of Gynaecological Oncological Trial groups

# Trials in cooperation with GOG-F

Trials done in cooperation with GOG-F (as of September 2024):

| | |
|---|---|
| TOTAL: | 45 |
| Ovarian cancer: | 21 |
| Endometrial cancer: | 14 |
| Cervical cancer: | 9 |
| Basket: | 1 |

# Cooperation with APGOT

APGOT
Asia-Pacific
Gynecologic Oncology
Trials Group

Gynaecological Cancer Academy

ENGOT
European Network of Gynaecological Oncological Trial groups

# Asia-Pacific Gynecologic Oncology Trials Group (APGOT)

- **Formed in 2019** with the idea of
- Performing **clinical trials highly focused on novel drugs** with good translational research **by Asia-Pacific investigators** collaborating with pharma industry.
- Attract **more trials to AP region** for the benefit of our patients

**Office in Singapore**

**Clinical chair**

- **Keiichi Fujiwara**

**Operational chair**

- **Yoonhee Bae**

**Academic groups**

- GCGS (Singapore)
- KGOG (Korea)
- GOTIC (Japan)
- ANZGOG (Australia)
- Kolgotrg (India)
- SGOG (China)
- TGOG (Taiwan)
- AGOG

# Trials done in cooperation with APGOT

- ENGOT-ov63/GINECO/NIRVANA
- ENGOT-ov77/GINECO/DS6000-109
- ENGOT-en13/GINECO/DOMENICA
- ENGOT-ov80/NCRI/DOVE

LACOG

LATIN AMERICAN COOPERATIVE
ONCOLOGY GROUP

*Infographic updated on 5/23/2024*

# LACOG MEMBERS

The **investigators** are an essential part of LACOG. We are **more than 600 members** from all over Latin America collaborating in observational studies and clinical trials. LACOG offers the possibility of Latin American investigators to develop new studies and participate in regional and international cancer trials.

ARGENTINA
**38**

BOLIVIA
**04**

BRAZIL
**425**

COLOMBIA
**19**

CHILE
**12**

COSTA RICA
**06**

CUBA
**02**

DOMINICAN REPUBLIC
**02**

ECUADOR
**03**

GUATEMALA
**06**

MEXICO
**28**

NICARAGUA
**01**

PARAGUAY
**01**

PERU
**20**

URUGUAY
**04**

VENEZUELA
**03**

TOTAL OF
**620**
INVESTIGATORS

# LACOG INFOGRAPHIC

MEMBERS
**620**

COUNTRIES
**17**

*Argentina, Brazil, Bolivia, Colombia, Chile, Costa Rica, Cuba, Dominican Republic, El Salvador, Ecuador, Guatemala, Mexico, Nicaragua, Panama, Peru, Uruguay and Venezuela*

**275**
HOSPITALS AND RESEARCH SITES

**MORE THAN 70**
EPIDEMIOLOGICAL STUDIES AND CLINICAL TRIALS

**MORE THAN 20.000**
PATIENTS ENROLLED

**MORE THAN 135**
ABSTRACTS AND ARTICLES PUBLISHED

**MORE THAN 30**
EDUCATIONAL EVENTS PERFORMED

*Infographic updated on 5/23/2024*

# 2023 STUDY-RELATED ACTIVITIES

**53**
**ONGOING STUDIES**

**119 sites**
open for recruitment in 9 different Latin American countries

- **Argentina: 16**
- **Brazil: 89**
- **Colombia: 03**
- **Chile: 02**
- **Dom. Rep.: 01**
- **Guatemala: 01**
- **Mexico: 04**
- **Peru: 02**
- **Uruguay: 01**

eCRFs developed
**6**

SIV
**62**

Monitoring visits
**216**

Signed contracts
**94**

Regulatory submissions
**1271**

# ENGOT ACHIEVEMENTS

# ENGOT achievements:

| As of Sep 2024 | |
|---|---|
| Trials per Tumour | |
| Ovarian | 92 |
| Endometrial | 29 |
| Cervical | 20 |
| Vulvar | 1 |
| Gynae basket | 10 |
| TOTAL | 152 |

| As of Sep 2024 | |
|---|---|
| Trials per Model | |
| Type A | 68 |
| Type B | 5 |
| Type C | 73 |
| Type D/C | 5 |
| Type D | 1 |
| TOTAL | 152 |

| Published and presented trials as of September 2024 |
|---|
| 55 |

ENGOT
European Network of Gynaecological Oncological Trial groups

# ENGOT patients recruitment statistics (as of March 2024)

- Ovarian: 87 trials, 30 919 patients recruited
- Endometrial: 26 trials, 6 546 patients recruited
- Cervical: 20 trials, 5 032 patients recruited
- Vulvar: 1 trial, 1 719 patients recruited
- Gyneacological/basket: 9 trials, 570 patients recruited

In total: **44 786 patients recruited**

***ENGOT recruits 67% involved patients compared to other groups***

ENGOT
European Network of Gynaecological Oncological Trial groups

# Standards in primary OC - who has defined it?

| | | |
|---|---|---|
| **Early ovarian cancer** | | |
| Surgical staging | Maggioni, EORTC/ACTION | |
| Standard chemotherapy | EORTC/ACTION | |
| **Advanced ovarian cancer** | | |
| Role of cytoreductive surgery | AGO metadatabase | AGO |
| Intervall-surgery | EORTC, CHORUS, TRUST | BGOG, NCRI, AGO |
| Lymphadenectomy | LION | AGO |
| Standard chemotherapy | Carboplatin/Paclitaxel (AGO-OVAR 3)<br>TC weekly (+/- Bev) (MITO 2/ICON 8) | AGO<br>MITO / NCRI |
| Bevacizumab | Carboplatin/Paclitaxel/Bevacizumab (ICON7)<br>Duration of Bev maintenance (AGO-OVAR 17) | NCRI<br>AGO |
| PARP-Inhibitors | TCB -> Bev + Olaparib (PAOLA1)<br>TC -> Niraparib (PRIMA)<br>TC-> Rucaparib (Athena) | GINECO<br>GEICO<br>NCRI |

ENGOT
European Network of Gynaecological Oncological Trial groups

# Standards in relapsed OC - Who has defined it?
# Platinum eligible relapse

| | | |
|---|---|---|
| Surgery for relapsed OC | DESKTOP I-III | AGO |
| Platinum vs non-platinum | MITO 8<br>INNOVATYON | MITO<br>MaNGO |
| Platinum-based therapy | Carboplatin/Paclitaxel (ICON4/AGO-OVAR 2.2)<br>Carboplatin/Gemcitabin (AGO-OVAR 2.5)<br>Carboplatin/PLD (CALYPSO) | NCRI/AGO<br>AGO<br>GINECO |
| Maintenance PARP-inhibitor | Niraparib (NOVA)<br>Olaparib (SOLO2)<br>PARP after PARP (OREO) | NSGO<br>GINECO<br>GINECO |
| Bevacizumab + Platinum combinations | Carbo/Gem/Bev (OCEANS)<br>Carbo/Pacli/Bev (GOG218)<br>Carbo/PLD/Bev (AGO-OVAR 2.21)<br>Bev after Bev (MITO 16b/MaNGO ov02) | <br><br>AGO<br>MITO/MaNGO |

ENGOT
European Network of Gynaecological Oncological Trial groups

# Standards in relapsed OC - Who has defined it?
# Platinum non-eligible relapse

| | | |
|---|---|---|
| Bevacizumab | Chemo + Bevacizumab (AURELIA) | GINECO |
| ADCs | Mirvetuximab (MIRASOL) | BGOG |
| Rare histologies<br>Low grade serous | Binimetinib (MILO) | BGOG |

ENGOT
European Network of Gynaecological Oncological Trial groups

# Standards in CC - Who has defined it?

| | | |
|---|---|---|
| Surgical techniques | SHAPE, FERTISS, ABRAX | ENGOT, CEEGOG |
| Role of SLN | SENTIX / SENTICOL III | CEEGOG, GINECO |
| Chemotherapy | Induction Chemo (Interlace) | NCRI |
| IO | Pembrolizumab adjuvant (KN-A18)<br>Atezolizumab (BEAT-CC) | MITO<br>GEICO |
| ADCs | Tistoumab Vedotin (TV 301) | BGOG |

ENGOT
European Network of Gynaecological Oncological Trial groups

# Standards in EC - Who has defined it?

| | | |
|---|---|---|
| Endocrine therapy | AI+CDK 4/6 (PALEO) | NSGO |
| IO metastatic | Dostarlimab (RUBY)<br>Atezolizumab (ATTEND)<br>DUO-E | NSGO<br>ManGO<br>BGOG |

ENGOT
European Network of Gynaecological Oncological Trial groups

# Practice changing publications

**>50 publications / congress presentations of ENGOT trials (as of May 2023)**



The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Timothy J. Perren, M.D., Ann Marie Swart, M.D., Jacobus Pfisterer, M.D., Jonathan A. Ledermann, M.D., Eric Pujade-Lauraine, M.D., Gunnar Kristensen, M.D., Mark S. Carey, M.D., Philip Beale, M.D., Andrés Cervantes, M.D., Christian Kurzeder, M.D., Andreas du Bois, M.D., Jalid Sehouli, M.D., Rainer Kimmig, M.D., Anne Stähle, M.D., Fiona Collinson, M.D., Sharadah Essapen, M.D., Charlie Gourley, M.D., Alain Lortholary, M.D., Frédéric Selle, M.D., Mansoor R. Mirza, M.D., Arto Leminen, M.D., Marie Plante, M.D., Dan Stark, M.D., Wendi Qian, Ph.D., Mahesh K.B. Parmar, Ph.D., and Amit M. Oza, M.D., for the ICON7 Investigators*



VOLUME 32 · NUMBER 13 · MAY 1 2014

JOURNAL OF CLINICAL ONCOLOGY | ORIGINAL REPORT

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

*Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias, Deolinda Pereira, Pauline Wimberger, Ana Oaknin, Mansoor Raza Mirza, Philippe Follana, David Bollag, and Isabelle Ray-Coquard*



ORIGINAL ARTICLE

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

P. Harter, J. Sehouli, D. Lorusso, A. Reuss, I. Vergote, C. Marth, J.-W. Kim, F. Raspagliesi, B. Lampe, G. Aletti, W. Meier, D. Cibula, A. Mustea, S. Mahner, I.B. Runnebaum, B. Schmalfeldt, A. Burges, R. Kimmig, G. Scambia, S. Greggi, F. Hilpert, A. Hasenburg, P. Hillemanns, G. Giorda, I. von Leffern, C. Schade-Brittinger, U. Wagner, and A. du Bois



Olaparib tablets as maintenance therapy in platinum-sensitive, relapsed ovarian cancer mutation (SOLO2/ENGOT-Ov21): a double-b randomised, placebo-controlled, phase 3 tri

*Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Ja Andrés Poveda, Sandro Pignata, Michael Friedlander, Nicoletta Colombo, Philipp Harter, Keiichi Fujiwara, Joyce Liu, Elizabeth S Lowe, Ralph Bloomfield, Patricia Pautier, the SOLO2/ENGOT-Ov21 investigators**

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

M.R. Mirza, B.J. Monk, J. Herrstedt, A.M. Oza, S. Mahner, A. Redondo, M. Fabbro, J.A. Ledermann, D. Lorusso, I. Vergote, N.E. Ben-Baruch, C. Marth, R. Mądry, R.D. Christensen, J.S. Berek, A. Dørum, A.V. Tinker, A. du Bois, A. González-Martín, P. Follana, B. Benigno, P. Rosenberg, L. Gilbert, B.J. Rimel, J. Buscema, J.P. Balser, S. Agarwal, and U.A. Matulonis, for the ENGOT-OV16/NOVA Investigators*



ORIGINAL ARTICLE

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

A. González-Martín, B. Pothuri, I. Vergote, R. DePont Christensen, W. Graybill, M.R. Mirza, C. McCormick, D. Lorusso, P. Hoskins, G. Freyer, K. Baumann, K. Jardon, A. Redondo, R.G. Moore, C. Vulsteke, R.E. O'Cearbhaill, B. Lund, F. Backes, P. Barretina-Ginesta, A.F. Haggerty, M.J. Rubio-Pérez, M.S. Shahin, G. Mangili, W.H. Bradley, I. Bruchim, K. Sun, I.A. Malinowska, Y. Li, D. Gupta, and B.J. Monk, for the PRIMA/ENGOT-OV26/GOG-3012 Investigators*

ENGOT
European Network of Gynaecological Oncological Trial groups

# ENGOT INITIATIVES

# ENGOT active initiatives

Translational Research (Biobank)

Rare Tumours

Early Drug Development (Phase I/II)

Gyneacological Cancer Academy (GCA)

Future Lead Investigators (FLI)

ENGOT
European Network of Gynaecological Oncological Trial groups

# Gynaecological Cancer Academy workshop (GCA)

- Educational programme aiming at the development of next generation of leaders within the clinical trial community.
- Young investigators learn how to design a trial, cooperate and conduct an analysis within the ENGOT framework.

- 13 GCA editions since 2013

- Current workshop: **November 13-15, 2024**, Stresa, Italy

- Expected outcome: research ideas that will be further developed.

GYNAECOLOGICAL CANCER ACADEMY

ENGOT
European Network of Gynaecological Oncological Trial groups

ENGOT
European Network of Gynaecological Oncological Trial groups

# ENGOT WEBINARS FOR CLINICAL COORDINATORS

engot.esgo.org

- 6 webinars held between May and November 2021

- Educational event for clinical project managers

- The topics were concentrated on organizational aspects of the clinical trials but also on the scientific content related to single tumour types











ENGOT
European Network of Gynaecological Oncological Trial groups

# ENGOT SUPPORT OF PATIENTS

engot.esgo.org

# ENGOT-ENGAGE webinar on clinical trials

- Educational event for patients, representatives of Patient advocacy groups
- 5 webinars held in 2022/2023, all recorded and still available
- The topics were presented to patients in a simpler/lay language




ENGAGe ESGO European Network of Gynaecological Cancer Advocacy Groups

ENGOT European Network of Gynaecological Oncological Trial groups

# https://engot.esgo.org/


ENGOT
European Network of
Gynaecological Oncological Trial groups

# THANK YOU!

ENGOT
European Network of
Gynaecological Oncological Trial groups

engot.esgo.org

The European Voice of Gynaecological Oncology